Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.

J Med Chem 2011 Feb 13;54(4):1071-9. Epub 2011 Jan 13.

GlaxoSmithKline Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy.

A large body of compelling preclinical evidence supports the clinical use of neurokinin (NK) receptor antagonists in a plethora of CNS and non-CNS therapeutic areas. The significant investment made in this area over the past 2 decades culminated with the observation that NK(1) receptor antagonists elicited clinical efficacy in major depression disorders. In addition, aprepitant (Merck) was launched as a new drug able to prevent chemotherapy-induced nausea and vomiting (CINV). After the discovery by GlaxoSmithKline of vestipitant, a wide drug discovery program was launched aimed at identifying additional clinical candidates. New compounds were designed to maximize affinity at the NK(1) receptor binding site while retaining suitable physicochemical characteristics to ensure excellent pharmacokinetic and pharmacodynamic properties in vivo. Herein we describe the discovery process of a new NK(1) receptor antagonist (casopitant) selected as clinical candidate and progressed into clinical studies to treat major depression disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm1013264DOI Listing
February 2011
17 Reads

Publication Analysis

Top Keywords

nk1 receptor
16
receptor antagonist
8
clinical candidate
8
major depression
8
receptor antagonists
8
depression disorders
8
clinical
6
receptor
5
program launched
4
discovery program
4
drug discovery
4
vestipitant wide
4
wide drug
4
launched aimed
4
aimed identifying
4
clinical candidates
4
efficacy major
4
additional clinical
4
identifying additional
4
glaxosmithkline vestipitant
4

Similar Publications